

CLAIMS

I claim,

1. A method, comprising:

a) providing: i) a patient having symptoms of chronic lymphocytic

5 leukemia, and ii) a formulation comprising an inhibitor that specifically inhibits  
Type 4 cyclic adenosine monophosphate phosphodiesterases; and

b) administering a therapeutically effective dose of said formulation  
to said patient under conditions such that said symptoms are reduced.

2. The method of Claim 1, wherein said administering is enteral  
10 administration.

3. The method of Claim 2, wherein said enteral administration is oral  
administration.

4. The method of Claim 1, wherein said administering is parenteral  
administration.

15 5. The method of Claim 1, wherein said patient is a naive patient.

6. The method of Claim 1, wherein said patient is immunocompromised.

7. The method of Claim 1, wherein said patient is unresponsive to  
chemotherapy with alkylating agents.

8. A method, comprising:

a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising rolapram; and

b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.

5

9. The method of Claim 8, wherein said administering is enteral administration.

10. The method of Claim 9, wherein said enteral administration is oral administration.

10

11. The method of Claim 8, wherein said administering is parenteral administration.

12. The method of Claim 8, wherein said patient is a naive patient.

13. The method of Claim 8, wherein said patient is immunocompromised.

15

14. The method of Claim 8, wherein said patient is unresponsive to chemotherapy with alkylating agents.